The global antacids market is expected to be worth US$ 6,971.2 million by the end of 2023 and further expand at a CAGR of 4.9% to reach a valuation of US$ 11,194.8 million by 2033.
According to a recent study by Future Market Insights, proton pump inhibitors are leading the market with a share of about 25.8% in the year 2022 within the global market.
Growth in the industry could be attributed to an increase in conditions like heartburn and GERD. The demand for over-the-counter digestive products to treat gastrointestinal disorders is rising as a result of the expanding trend toward self-medication.
| Attribute | Details |
|---|---|
| Antacids Market Size, 2022 | US$ 6,646.9 million |
| Antacids Market Size, 2023 | US$ 6,971.2 million |
| Antacids Market Size, 2033 | US$ 11,194.8 million |
| Value CAGR (2023 to 2033) | 4.9% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
An Increase in the Geriatric Population
Globally, the geriatric population is increasing rapidly, leading to an increase in various clinical conditions like acidity problems. For instance, report published by Economics and Social Affairs, 2020, globally, there were 727 million people 65 years of age or older in 2020. By 2050, it is anticipated that this number will have more than doubled, reaching over 1.5 billion people.
Symptomatic disorders like oesophageal cancer and Barrett's esophagus are relatively common in such people. To cure these diseases, a combination of therapies is implemented, and antacid use in these cases has significantly increased, likely to fuel market expansion throughout the projection period.
Factors Restraining Demand for Antacids
Antacids frequently cause milk-alkali syndrome and dose-dependent rebound hyperacidity as side effects. The detrimental impact of antacids containing aluminum hydroxide cause aluminum poisoning, constipation, osteomalacia, and hypophosphatemia. It is projected that the increasing concerns about these harmful side effects slow the expansion of the market.
Antacids also cause the absorption of other acid-reducing medications when taken with them, which reduces their effectiveness.
The antacids market recorded a growth of around 4.7% and reached a valuation of US$ 6,646.9 million in 2022. The sale of antacids expanded owing to cases of heartburn, gastric ulcers, and ingestion.
| Antacids Market Size, 2022 | US$ 6,646.9 million |
|---|
New drugs that support the market's expansion are being developed by researchers. Eminent market participants make significant contributions to drug development and discovery.
Thus, owing to the factors mentioned above, the global market is expected to grow at a rate of 4.9% during the forecast period from 2023 to 2033
Principal Consultant
| Countries | Market Share |
|---|---|
| United States | 28.1% |
| China | 6.1% |
| India | 4.5% |
| Germany | 6.2% |
| United Kingdom | 5.2% |
The United States holds around 28.1% share of the global market and is projected for continued profitable growth.
The prevalence of gastrointestinal issues is on the rise, and antacid products are becoming widely known among consumers in the United States. However, the availability of effective treatment options and the presence of numerous manufacturers in the United States market has made this one of the key areas in the antacid market.
For instance, in a report published by the Centers for Disease Control and Prevention on 13 September 2021, in the United States, there are 8 million visits to emergency departments when digestive issues are the primary diagnosis as of 2019.
China is set to exhibit a growth rate of nearly 6.1% over the forecast period due to the rise in the geriatric population and the extensive utilization of antacids to relieve GERD-related issues.
One of the world's fastest-growing aging populations is in China. For instance, records stated by the World Health Organization (WHO), By 2040, it is anticipated that 28% of China's population will be over 60. A significant increase in the country's geriatric population has led to China experiencing substantial growth in the artificial tears market.
India is set to exhibit a CAGR of nearly 4.3% globally, with a market share of 4.5% in 2022.
In India, substantial financing and the launch of several healthcare programs, like Pradhan Mantri Jan Arogya Yojana and Ayushman Bharat, which offer accessible healthcare facilities and reimbursement options to patients receiving healthcare treatment, are boosting the demand for the market. Increasing disposable income in middle-class families enables them to spend more money on their healthcare expenditure to get high-quality treatment facilities. The pharmaceutical sector has continuously seen lucrative growth in the Research and Development sector.
| By Drug Class | Market Share |
|---|---|
| Proton Pump Inhibitors | 25.3% |
| H2 Antagonist | 21% |
| Acid Neutralizers | 18.5% |
| Pro-Motility Agents | 8% |
| Anti-H.Pyrolic Drugs | 13.7% |
| Prostaglandin Analogous | 10.3% |
| Others | 3.3% |
Proton pump inhibitors are expected to present high growth at a CAGR of 4.5% by the end of the forecast period, with a market share of 25.3% by the end of 2022. Proton pump inhibitors are a class of medication that reduces the amount of stomach acid produced by glands in the lining of the stomach. Furthermore, it reduces the effects of acid reflux on the lower esophagus.
Tablets hold a market share of 25.5% in 2022 and are expected to display gradual growth over the forecast period, with an estimated CAGR of 4.4% by 2033. Tablets are the easiest way to consume the drug, and it is safe. To treat indigestion and heartburn, antacids work by neutralizing the acid in your stomach. Tablets of antacids cure indigestion and heartburn and work by neutralizing the acid in the stomach
The oral route of administration usage is more as compared to injectables. Oral holds a prominent market share of 64.4% during the year 2022, a CAGR of 4.7% by the end of the forecast period. Owing to its advantages, such as patient compliance, non-invasiveness, and convenience of drug administration, the oral route of administration is the most favored method.
Gastroesophageal reflux disease holds a market share of 49.2% in 2022 and is expected to display gradual growth over the forecast period, with an estimated CAGR of 4.7% in 2033. When stomach acid repeatedly flows back into the tube between the stomach and mouth, it causes gastroesophageal reflux disease. The rising cases of typical GERD symptoms include heartburn, so it holds a prominent position in the market segment.
Retail pharmacies held a prominent market share of 44.0% in 2022, with a CAGR of 4.4% in the forecast period. The prominent market share is expected to be held by retail pharmacies. This is primarily due to the continuing higher dependency on pharmacies, dominant fragment, propelling sales of the overall market. Retail pharmacy stores hold a variety of products of different brands and can be easily located near the residential area, hence gaining the prominent position in the distribution channel based on the share of the market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The market for the production of antacids is fragmented, with several competitors. These businesses are employing strategies including collaborations, partnerships, mergers and acquisitions, and new drug releases to satisfy consumer demand and increase their client base.
Recent Development
| Attribute | Details |
|---|---|
| Forecast Period | 2018 to 2022 |
| Historical Data Available for | 2023 to 2033 |
| Market Analysis | US$ million for Value |
| Key Regions Covered | North America, Latin America, Europe, South Asia, East Asia, Oceania, and Middle East & Africa |
| Key Countries Covered | United States, Canada, Brazil, Mexico, Argentina, United Kingdom, Germany, Italy, Russia, Spain, France, BENELUX, Nordic countries, India, Thailand, Indonesia, Malaysia, Japan, China, South Korea, Australia, New Zealand, Turkey, GCC, Israel, South Africa and North Africa |
| Key Market Segments Covered | Drug Class, Dosage Form, Route of Administration, Indication, Distribution Channel and Region |
| Key Companies Profiled |
|
| Pricing | Available upon Request |
The global antacids market was worth US$ 6,646.9 million in 2022.
The rising prevalence of gastric diseases, growing cases of heartburn, and gastric ulcers.
The United States, China, India, Germany, and the United Kingdom are top countries.
The sales revenue of the antacids market is expected to register a 4.9% CAGR.
Johnson and Johnson, Sanofi S.A., Bayer AG, and Sun Pharmaceuticals Ltd are a few key players in the antacids industry.
The United States accounts for about 90.9% of the North American antacids market in 2022.
From 2017 to 2022, the market for antacids expanded at the rate of 3.5%.
India accounts for about 4.3% of market share in 2022 in the antacids market.
1. Executive Summary 1.1. Global Market Outlook 1.2. Demand Side Trends 1.3. Supply Side Trends 1.4. Market Round Offs 1.5. FMI Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 2.3. Inclusions/Exclusions 3. Brand Mapping Analysis 3.1. Price v/s Drug Class 3.2. Value for Money 3.3. Top of Mind Antacid Brand 3.4. Brand Portfolio-by Key Players 3.5. Brand Loyalty Mapping 3.6. Route of Administration Pattern Overview 3.7. Branded vs Unbranded-Market Mix 4. Distribution Channel Wise Key Brand Positioning 4.1. Global Top Retailers and their Brand Offerings 4.1.1. Retail Pharmacies 4.1.2. Hospital Pharmacies 4.1.3. Online Pharmacies 4.2. Retail Pricing Strategies 5. Consumer Buying Behavior Analysis 5.1. Functionality and Drug Class Demand 5.1.1. Proton Pump Inhibitors 5.1.2. H2 Antagonist 5.1.3. Acid Neutralizers 5.1.4. Pro-Motility Agents 5.1.5. Anti-H.Pyrolic Drugs 5.1.6. Prostaglandin Analogous 5.1.7. Others 5.2. What factors do you consider when deciding to purchase antacid? 5.3. How important are product certifications when choosing antacid? 5.4. How important is the brand reputation and recognition when selecting antacid? 5.5. What marketing channels do you prefer for learning about new antacid? 5.6. How often do you purchase new antacid? 5.6.1. Once or More Every Month 5.6.2. Once Every 2 months 5.6.3. Once Every 6 Months 5.6.4. Once a Year 5.6.5. Less Than Once A Year 6. Market Trends & Dynamics 6.1. Per capita spending on antacid 6.2. Key Trends Impacting the Market 6.3. Drug Class Innovation / Development Trends 6.3.1. Latest Trends and Demands 6.3.2. Latest Innovations and New Launches 6.4. Future Prospects of 6.5. Market Dynamics 6.5.1. Drivers 6.5.2. Restraints 6.5.3. Opportunity Analysis 7. Value Added Insights 7.1. Drug Class Adoption Analysis 7.2. Diabetes Epidemiology 7.3. New Drug Class Approvals/ Launches 7.4. Regulatory Landscape 7.5. PESTEL Analysis 7.6. Porter’s Analysis 7.7. Value Chain Analysis 8. Market Background 8.1. Macro-Economic Factors 8.1.1. Global GDP Growth Outlook 8.1.2. Global Healthcare Expenditure 8.1.3. Global Gastrointestinal Therapeutics Market Overview 8.2. Forecast Factors - Relevance & Impact 8.2.1. Top Companies Historical Growth 8.2.2. Pharmaceutical spending 8.2.3. Adoption of Antacid 8.2.4. Drug Class Pricing 8.2.5. Drug Class & Stock Availability 8.2.6. Rise in number of stomach ulcer 8.2.7. Companies Increasingly Spending on R&D and Focus on Innovation 8.2.8. Collaborations and Agreements between Manufacturers 9. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033 9.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022 9.2. Current and Future Market Value (US$ Million) Projections, 2023 to 2033 9.2.1. Y-o-Y Growth Trend Analysis 9.2.2. Absolute $ Opportunity Analysis 10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Drug Class 10.1. Introduction / Key Findings 10.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033 10.3.1. Proton Pump Inhibitors 10.3.2. H2 Antagonist 10.3.3. Acid Neutralizers 10.3.4. Pro-Motility Agents 10.3.5. Anti-H.Pyrolic Drugs 10.3.6. Prostaglandin Analogous 10.3.7. Others 10.4. Market Attractiveness Analysis By Drug Class 11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration 11.1. Introduction / Key Findings 11.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2017 to 2022 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033 11.3.1. oral 11.3.2. Injectable 11.4. Market Attractiveness Analysis By Route of Administration 12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Dosage Form 12.1. Introduction / Key Findings 12.2. Historical Market Size (US$ Million) Analysis By Dosage Form, 2017 to 2022 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Dosage Form, 2023 to 2033 12.3.1. Tablet 12.3.2. Capsules 12.3.3. Powder 12.3.4. Liquid 12.3.5. Others 12.4. Market Attractiveness Analysis By Dosage Form 13. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication 13.1. Introduction / Key Findings 13.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033 13.3.1. Gastroesophageal Reflux Disease 13.3.2. Heartburn 13.3.3. Peptic Ulcer 13.3.4. Others 13.4. Market Attractiveness Analysis By Indication 14. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel 14.1. Introduction / Key Findings 14.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 14.3.1. Retail Pharmacies 14.3.2. Hospital Pharmacies 14.3.3. Online Pharmacies 14.4. Market Attractiveness Analysis By Distribution Channel 15. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region 15.1. Introduction 15.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033 15.3.1. North America 15.3.2. Latin America 15.3.3. Europe 15.3.4. South Asia 15.3.5. East Asia 15.3.6. Oceania 15.3.7. Middle East & Africa 15.4. Market Attractiveness Analysis By Region 16. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 16.1. Introduction 16.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 16.3.1. By Country 16.3.1.1. USA 16.3.1.2. Canada 16.3.2. By Drug Class 16.3.3. By Route of Administration 16.3.4. By Dosage Form 16.3.5. By Indication 16.3.6. By Distribution Channel 16.4. Market Attractiveness Analysis 16.4.1. By Country 16.4.2. By Drug Class 16.4.3. By Route of Administration 16.4.4. By Dosage Form 16.4.5. By Indication 16.4.6. By Distribution Channel 16.5. Market Trends 16.6. Market Drivers & Restraints – Intensity Mapping 16.7. Country Level Analysis & Forecast 16.7.1. USA Market 16.7.1.1. Introduction 16.7.1.2. Market Analysis and Forecast by Market Taxonomy 16.7.1.2.1. By Drug Class Type 16.7.1.2.2. By Route of Administration 16.7.1.2.3. By Dosage Form 16.7.1.2.4. By Indication 16.7.1.2.5. By Distribution Channel 16.7.2. Canada Market 16.7.2.1. Introduction 16.7.2.2. Market Analysis and Forecast by Market Taxonomy 16.7.2.2.1. By Drug Class Type 16.7.2.2.2. By Route of Administration 16.7.2.2.3. By Dosage Form 16.7.2.2.4. By Indication 16.7.2.2.5. By Distribution Channel 17. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033 17.1. Introduction 17.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 17.3.1. By Country 17.3.1.1. Brazil 17.3.1.2. Mexico 17.3.1.3. Argentina 17.3.1.4. Rest of LATAM 17.3.2. By Drug Class 17.3.3. By Route of Administration 17.3.4. By Dosage Form 17.3.5. By Indication 17.3.6. By Distribution Channel 17.4. Market Attractiveness Analysis 17.4.1. By Country 17.4.2. By Drug Class 17.4.3. By Route of Administration 17.4.4. By Dosage Form 17.4.5. By Indication 17.4.6. By Distribution Channel 17.5. Market Trends 17.6. Market Drivers & Restraints – Intensity Mapping 17.7. Country Level Analysis & Forecast 17.7.1. Brazil Market 17.7.1.1. Introduction 17.7.1.2. Market Analysis and Forecast by Market Taxonomy 17.7.1.2.1. By Drug Class Type 17.7.1.2.2. By Route of Administration 17.7.1.2.3. By Dosage Form 17.7.1.2.4. By Indication 17.7.1.2.5. By Distribution Channel 17.7.2. Mexico Market 17.7.2.1. Introduction 17.7.2.2. Market Analysis and Forecast by Market Taxonomy 17.7.2.2.1. By Drug Class Type 17.7.2.2.2. By Route of Administration 17.7.2.2.3. By Dosage Form 17.7.2.2.4. By Indication 17.7.2.2.5. By Distribution Channel 17.7.3. Argentina Market 17.7.3.1. Introduction 17.7.3.2. Market Analysis and Forecast by Market Taxonomy 17.7.3.2.1. By Drug Class Type 17.7.3.2.2. By Route of Administration 17.7.3.2.3. By Dosage Form 17.7.3.2.4. By Indication 17.7.3.2.5. By Distribution Channel 18. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033 18.1. Introduction 18.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 18.3.1. By Country 18.3.1.1. UK 18.3.1.2. Germany 18.3.1.3. France 18.3.1.4. Italy 18.3.1.5. Spain 18.3.1.6. BENELUX 18.3.1.7. Russia 18.3.1.8. Rest of Europe 18.3.2. By Drug Class 18.3.3. By Route of Administration 18.3.4. By Dosage Form 18.3.5. By Indication 18.3.6. By Distribution Channel 18.4. Market Attractiveness Analysis 18.4.1. By Country 18.4.2. By Drug Class 18.4.3. By Route of Administration 18.4.4. By Dosage Form 18.4.5. By Indication 18.4.6. By Distribution Channel 18.5. Market Trends 18.6. Market Drivers & Restraints – Intensity Mapping 18.7. Country Level Analysis & Forecast 18.7.1. UK Market 18.7.1.1. Introduction 18.7.1.2. Market Analysis and Forecast by Market Taxonomy 18.7.1.2.1. By Drug Class Type 18.7.1.2.2. By Route of Administration 18.7.1.2.3. By Dosage Form 18.7.1.2.4. By Indication 18.7.1.2.5. By Distribution Channel 18.7.2. Germany Market 18.7.2.1. Introduction 18.7.2.2. Market Analysis and Forecast by Market Taxonomy 18.7.2.2.1. By Drug Class Type 18.7.2.2.2. By Route of Administration 18.7.2.2.3. By Dosage Form 18.7.2.2.4. By Indication 18.7.2.2.5. By Distribution Channel 18.7.3. France Market 18.7.3.1. Introduction 18.7.3.2. Market Analysis and Forecast by Market Taxonomy 18.7.3.2.1. By Drug Class Type 18.7.3.2.2. By Route of Administration 18.7.3.2.3. By Dosage Form 18.7.3.2.4. By Indication 18.7.3.2.5. By Distribution Channel 18.7.4. Spain Market 18.7.4.1. Introduction 18.7.4.2. Market Analysis and Forecast by Market Taxonomy 18.7.4.2.1. By Drug Class Type 18.7.4.2.2. By Route of Administration 18.7.4.2.3. By Dosage Form 18.7.4.2.4. By Indication 18.7.4.2.5. By Distribution Channel 18.7.5. Italy Market 18.7.5.1. Introduction 18.7.5.2. Market Analysis and Forecast by Market Taxonomy 18.7.5.2.1. By Drug Class Type 18.7.5.2.2. By Route of Administration 18.7.5.2.3. By Dosage Form 18.7.5.2.4. By Indication 18.7.5.2.5. By Distribution Channel 18.7.6. BENELUX Market 18.7.6.1. Introduction 18.7.6.2. Market Analysis and Forecast by Market Taxonomy 18.7.6.2.1. By Drug Class Type 18.7.6.2.2. By Route of Administration 18.7.6.2.3. By Dosage Form 18.7.6.2.4. By Indication 18.7.6.2.5. By Distribution Channel 18.7.7. Russia Market 18.7.7.1. Introduction 18.7.7.2. Market Analysis and Forecast by Market Taxonomy 18.7.7.2.1. By Drug Class Type 18.7.7.2.2. By Route of Administration 18.7.7.2.3. By Dosage Form 18.7.7.2.4. By Indication 18.7.7.2.5. By Distribution Channel 19. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 19.1. Introduction 19.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 19.3.1. By Country 19.3.1.1. China 19.3.1.2. Japan 19.3.1.3. South Korea 19.3.2. By Drug Class 19.3.3. By Route of Administration 19.3.4. By Dosage Form 19.3.5. By Indication 19.3.6. By Distribution Channel 19.4. Market Attractiveness Analysis 19.4.1. By Country 19.4.2. By Drug Class 19.4.3. By Route of Administration 19.4.4. By Dosage Form 19.4.5. By Indication 19.4.6. By Distribution Channel 19.5. Market Trends 19.6. Market Drivers & Restraints – Intensity Mapping 19.7. Country Level Analysis & Forecast 19.7.1. China Market 19.7.1.1. Introduction 19.7.1.2. Market Analysis and Forecast by Market Taxonomy 19.7.1.2.1. By Drug Class Type 19.7.1.2.2. By Route of Administration 19.7.1.2.3. By Dosage Form 19.7.1.2.4. By Indication 19.7.1.2.5. By Distribution Channel 19.7.2. Japan Market 19.7.2.1. Introduction 19.7.2.2. Market Analysis and Forecast by Market Taxonomy 19.7.2.2.1. By Drug Class Type 19.7.2.2.2. By Route of Administration 19.7.2.2.3. By Dosage Form 19.7.2.2.4. By Indication 19.7.2.2.5. By Distribution Channel 19.7.3. South Korea Market 19.7.3.1. Introduction 19.7.3.2. Market Analysis and Forecast by Market Taxonomy 19.7.3.2.1. By Drug Class Type 19.7.3.2.2. By Route of Administration 19.7.3.2.3. By Dosage Form 19.7.3.2.4. By Indication 19.7.3.2.5. By Distribution Channel 20. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033 20.1. Introduction 20.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 20.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 20.3.1. By Country 20.3.1.1. India 20.3.1.2. Indonesia 20.3.1.3. Thailand 20.3.1.4. Malaysia 20.3.1.5. Rest of South Asia 20.3.2. By Drug Class 20.3.3. By Route of Administration 20.3.4. By Dosage Form 20.3.5. By Indication 20.3.6. By Distribution Channel 20.4. Market Attractiveness Analysis 20.4.1. By Country 20.4.2. By Drug Class 20.4.3. By Route of Administration 20.4.4. By Dosage Form 20.4.5. By Indication 20.4.6. By Distribution Channel 20.5. Market Trends 20.6. Market Drivers & Restraints – Intensity Mapping 20.7. Country Level Analysis & Forecast 20.7.1. India Market 20.7.1.1. Introduction 20.7.1.2. Market Analysis and Forecast by Market Taxonomy 20.7.1.2.1. By Drug Class Type 20.7.1.2.2. By Route of Administration 20.7.1.2.3. By Dosage Form 20.7.1.2.4. By Indication 20.7.1.2.5. By Distribution Channel 20.7.2. Indonesia Market 20.7.2.1. Introduction 20.7.2.2. Market Analysis and Forecast by Market Taxonomy 20.7.2.2.1. By Drug Class Type 20.7.2.2.2. By Route of Administration 20.7.2.2.3. By Dosage Form 20.7.2.2.4. By Indication 20.7.2.2.5. By Distribution Channel 20.7.3. Thailand Market 20.7.3.1. Introduction 20.7.3.2. Market Analysis and Forecast by Market Taxonomy 20.7.3.2.1. By Drug Class Type 20.7.3.2.2. By Route of Administration 20.7.3.2.3. By Dosage Form 20.7.3.2.4. By Indication 20.7.3.2.5. By Distribution Channel 20.7.4. Malaysia Market 20.7.4.1. Introduction 20.7.4.2. Market Analysis and Forecast by Market Taxonomy 20.7.4.2.1. By Drug Class Type 20.7.4.2.2. By Route of Administration 20.7.4.2.3. By Dosage Form 20.7.4.2.4. By Indication 20.7.4.2.5. By Distribution Channel 21. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033 21.1. Introduction 21.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 21.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 21.3.1. By Country 21.3.1.1. Australia 21.3.1.2. New Zealand 21.3.2. By Drug Class 21.3.3. By Route of Administration 21.3.4. By Dosage Form 21.3.5. By Indication 21.3.6. By Distribution Channel 21.4. Market Attractiveness Analysis 21.4.1. By Country 21.4.2. By Drug Class 21.4.3. By Route of Administration 21.4.4. By Dosage Form 21.4.5. By Indication 21.4.6. By Distribution Channel 21.5. Market Trends 21.6. Market Drivers & Restraints – Intensity Mapping 21.7. Country Level Analysis & Forecast 21.7.1. Australia Market 21.7.1.1. Introduction 21.7.1.2. Market Analysis and Forecast by Market Taxonomy 21.7.1.2.1. By Drug Class Type 21.7.1.2.2. By Route of Administration 21.7.1.2.3. By Dosage Form 21.7.1.2.4. By Indication 21.7.1.2.5. By Distribution Channel 21.7.2. New Zealand Market 21.7.2.1. Introduction 21.7.2.2. Market Analysis and Forecast by Market Taxonomy 21.7.2.2.1. By Drug Class Type 21.7.2.2.2. By Route of Administration 21.7.2.2.3. By Dosage Form 21.7.2.2.4. By Indication 21.7.2.2.5. By Distribution Channel 22. Middle East & Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033 22.1. Introduction 22.2. Historical Market Size (US$ Million) and Volume (Units) Trend Analysis By Market Taxonomy, 2017 to 2022 22.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033 22.3.1. By Country 22.3.1.1. GCC Countries 22.3.1.2. Türkiye 22.3.1.3. South Africa 22.3.1.4. North Africa 22.3.1.5. Rest of MEA 22.3.2. By Drug Class 22.3.3. By Route of Administration 22.3.4. By Dosage Form 22.3.5. By Indication 22.3.6. By Distribution Channel 22.4. Market Attractiveness Analysis 22.4.1. By Country 22.4.2. By Drug Class 22.4.3. By Route of Administration 22.4.4. By Dosage Form 22.4.5. By Indication 22.4.6. By Distribution Channel 22.5. Market Trends 22.6. Market Drivers & Restraints – Intensity Mapping 22.7. Country Level Analysis & Forecast 22.7.1. GCC Countries Market 22.7.1.1. Introduction 22.7.1.2. Market Analysis and Forecast by Market Taxonomy 22.7.1.2.1. By Drug Class Type 22.7.1.2.2. By Route of Administration 22.7.1.2.3. By Dosage Form 22.7.1.2.4. By Indication 22.7.1.2.5. By Distribution Channel 22.7.2. Türkiye Market 22.7.2.1. Introduction 22.7.2.2. Market Analysis and Forecast by Market Taxonomy 22.7.2.2.1. By Drug Class Type 22.7.2.2.2. By Route of Administration 22.7.2.2.3. By Dosage Form 22.7.2.2.4. By Indication 22.7.2.2.5. By Distribution Channel 22.7.3. South Africa Market 22.7.3.1. Introduction 22.7.3.2. Market Analysis and Forecast by Market Taxonomy 22.7.3.2.1. By Drug Class Type 22.7.3.2.2. By Route of Administration 22.7.3.2.3. By Dosage Form 22.7.3.2.4. By Indication 22.7.3.2.5. By Distribution Channel 22.7.4. North Africa Market 22.7.4.1. Introduction 22.7.4.2. Market Analysis and Forecast by Market Taxonomy 22.7.4.2.1. By Drug Class Type 22.7.4.2.2. By Route of Administration 22.7.4.2.3. By Dosage Form 22.7.4.2.4. By Indication 22.7.4.2.5. By Distribution Channel 23. Market Structure Analysis 23.1. Market Analysis by Tier of Companies 23.2. Market Share Analysis of Top Players 23.3. Market Presence Analysis 24. Competition Analysis 24.1. Competition Dashboard 24.2. Branding and Promotional Strategies, By Key Players 24.3. Key Development Analysis 24.4. Competition Deep Dive 24.4.1. Johnson and Johnson 24.4.1.1. Overview 24.4.1.2. Drug Class Portfolio 24.4.1.3. Key Financials 24.4.1.4. Sales Footprint 24.4.1.5. Strategy Overview 24.4.2. Sanofi S.A. 24.4.3. Bayer AG 24.4.4. Sun Pharmaceuticals Ltd 24.4.5. Zydus Lifesciences 24.4.6. Abbott Laboratories 24.4.7. AstraZeneca plc 24.4.8. Boehringer Ingelheim International GmbH 24.4.9. Dr. Reddy’s Laboratories Ltd. 24.4.10. GlaxoSmithKline pl 24.4.11. Pfizer Inc 24.4.12. Procter & Gamble Company 24.4.13. Reckitt Benckiser Group PLC 24.4.14. Takeda Pharmaceutical Company Limited 24.4.15. F. Hoffmann-La Roche Ltd 24.4.16. Mylan N.V 24.4.17. Hikma Pharmaceuticals PLC 24.4.18. Teva Pharmaceutical Industries Ltd. 24.4.19. Bristol Myers Squibb Company 24.4.20. Novartis AG 24.4.21. Lupin, Cipla Inc 24.4.22. Aurobindo Pharma 24.4.23. Fresenius Kabi AG and Alkem Labs 25. Assumptions and Acronyms Used 26. Research Methodology
Explore Healthcare Insights
View Reports
Antacids Market
